We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

U.S. Listing | Veterinary vaccine enterprise from Jilin, Zhengye Biotech, files for U.S. IPO, plans to list on Nasdaq

U.S. Listing | Veterinary vaccine enterprise from Jilin, Zhengye Biotech, files for U.S. IPO, plans to list on Nasdaq

Golden Box Group | Listing Guidance | US Listing | IPO | SPAC | RTO | US Listing | Professional US Listing Guidance Institution | US Stock Listing |

Today's Quick Overview of US Listing News!

On January 9, 2024, Zhengye Biotechnology Holding Limited from Jilin (hereinafter referred to as: Zhengye Biotechnology) submitted a prospectus to the U.S. Securities and Exchange Commission (SEC) applying for an IPO listing on the Nasdaq with the stock code ZYBT.

a4d539286d67775e886b1cd18c3d32c9_640_wx_fmt=png&from=appmsg&wxfrom=5&wx_lazy=1&wx_co=1.png

Company Profile

c4448a5372de7ed2e1dd6ed98489aa4f_640_wx_fmt=png&from=appmsg&wxfrom=5&wx_lazy=1&wx_co=1.png

Zhengye Biotechnology focuses on the research, development, manufacturing and sales of veterinary vaccines through its operating entity, with a focus on livestock vaccines. For nearly 20 years, Zhengye Biotechnology has been committed to enhancing the health of livestock. The company sells a variety of vaccines, including vaccines for pigs, cattle, goats, sheep, poultry and dogs. Zhengye Biotechnology's products cover 29 provinces across China and are exported to overseas markets such as Vietnam, Pakistan and Egypt.

For the six months ended June 30, 2023, and the fiscal years ended December 31, 2022 and 2021, Zhengye Biotechnology's revenue was RMB 116.9 million (USD 16.1 million), RMB 260.3 million (USD 37.7 million) and RMB 214.1 million (USD 31.0 million) respectively.

Company Structure

aad6809de19f83fa3721ed6a90640605_640_wx_fmt=png&from=appmsg&wxfrom=5&wx_lazy=1&wx_co=1.png

(1) 10,000,000 ordinary shares held by Securingium Holding Limited, of which (i) 0.01% is owned by Jiahe Developments Limited, which is itself 100% owned by Han Zhenfa, and (ii) 99.99% is owned by TSset Holding Limited, which, as of the date of this prospectus, is 100% owned by Trident Trust Company (HK) Limited, which acts as the trustee of Generations United Trust. The settlor, beneficiaries and protector of Generations United Trust is Han Zhenfa.

(2) 570,830 ordinary shares held by VVAX Holdings Limited, which is 100% owned by Jilin Zhengye Group Co., Ltd., of which 99% is owned by Han Zhenfa and 1% is owned by Sun Lihua.

(3) 569,688 ordinary shares held by Vanguards Skyline Holdings Limited, which is 100% owned by Changchun Feier Investment Center (Limited Partnership), of which 64.81% is owned by Han Zhenfa. As of the date of signing this prospectus, Changchun Feier Investment Center (Limited Partnership) is ultimately controlled by its managing partner, Han Zhenfa.

(4) 259,465 ordinary shares held by TLjinmao Limited, which is 100% owned by Nanjing Tailong Jinmao Pharmaceutical Industry Investment Enterprise (Limited Partnership), a private equity fund established and managed by Tibet Jinmao Investment Management Co., Ltd. Tibet Jinshe Investment Management Co., Ltd. is a Chinese private equity fund management company focusing on investment management and financial information consulting.

(5) 16,611 ordinary shares held by XZjinyuan Limited, which is 100% owned by Tibet Jinyuan Investment Management Co., Ltd., a Chinese private equity fund management company focusing on investment management and financial information consulting.

(6)  Jilin Zhengye is held by Hainan Senhan with 58.6890%, Windsor Holdings with 25.1524%, Jilin Economic and Technological Development Zone Economic and Technological Development Corporation with 15.2439%, Jilin Jinqiao Investment Co., Ltd. with 0.9146%, and Liu Yufeng with 0.0001%.

Financial Conditions

Compared with the years ended December 31, 2022 and December 31, 2021, and compared with the six months ended June 30, 2023 and the six months ended June 30, 2022.

Net Revenue

Zhengye Bio’s revenue increased by 21.6% from RMB 214.1 million (US$31 million) for the year ended December 31, 2021 to RMB 260.3 million (US$37.7 million) for the year ended December 31, 2022, mainly due to the increase in revenue from higher sales of pig vaccines.

Zhengye Bio’s revenue decreased by 5.3% from RMB 123.4 million (US$17 million) for the six months ended June 30, 2022 to RMB 116.9 million (US$16.1 million) for the six months ended June 30, 2023, mainly due to the decrease in revenue from lower sales of pig vaccines.

Cost of Revenue

Zhengye Bio’s cost of revenue increased from RMB 88.7 million (US$12.9 million) for the year ended December 31, 2021 to RMB 106.8 million (US$15.5 million) for the year ended December 31, 2022, a roughly commensurate increase due to higher net revenue resulting from increased product subscriptions from operating entities.

Zhengye Bio’s cost of revenue decreased by 4.5% from RMB 46.5 million (US$6.4 million) for the six months ended June 30, 2022 to RMB 44.4 million (US$6.1 million) for the six months ended June 30, 2023, due to lower net revenue resulting from reduced product subscriptions from operating entities.

Gross Profit

Zhengye Bio’s gross profit increased from RMB 125.4 million (US$18.2 million) for the year ended December 31, 2021 to RMB 153.5 million (US$22.3 million) for the year ended December 31, 2022. The gross margin increased from 58.9% for the year ended December 31, 2021 to 59.2% for the year ended December 31, 2022, mainly due to higher revenue from high-margin pig vaccines.

Zhengye Bio’s gross profit decreased from RMB 76.8 million (US$10.6 million) for the six months ended June 30, 2022 to RMB 72.5 million (US$10 million) for the six months ended June 30, 2023.

aa343ef4e257c5b745370558451af5b4_640_wx_fmt=png&from=appmsg&wxfrom=5&wx_lazy=1&wx_co=1.png93ae8aa37afd489e3bf92c045b7e0d57_640_wx_fmt=png&from=appmsg&wxfrom=5&wx_lazy=1&wx_co=1.png

Intermediary Institutions

The intermediary team for Zhengye Biotech's IPO mainly includes:

Underwriter: US Tiger Securities, Inc.

Auditor: WWC, P.C.

Company's Chinese Counsel: Guantao Law Firm Hangzhou Office

Company's US Counsel: Hunter Taubman Fischer & Li LLC

Company's Cayman Counsel: Conyers Dill & Pearman

Brokerage Firm's US Counsel: VCL Law LLP

Brokerage Firm's Chinese Counsel: Jincheng Tongda & Neal Law Firm

Chinese concept stocks' US listings rebound,the approval process for overseas issuance and listing filings of enterprises has accelerated,in2023the US stock market has seen strong gains,Chinese companies' confidence in listing in the US is growing. Xiaojin from Gold Box Group will share daily hot information on US listings to help enterprises soar in their listings!

尾图新.jpg

Disclaimer: Some information in this article is sourced from the internet. The content published in this article is for sharing purposes only. If there are any issues involving content or copyright, please contact us and we will handle it as soon as possible.

Originally published on 金盒企业管理集团